1. Home
  2. LRN vs NAMS Comparison

LRN vs NAMS Comparison

Compare LRN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stride Inc.

LRN

Stride Inc.

HOLD

Current Price

$79.61

Market Cap

3.5B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$20.69

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRN
NAMS
Founded
2000
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
2.8B
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
LRN
NAMS
Price
$79.61
$20.69
Analyst Decision
Hold
Strong Buy
Analyst Count
3
16
Target Price
★ $102.50
$49.93
AVG Volume (30 Days)
878.3K
★ 1.4M
Earning Date
10-20-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
★ 32.81
EPS
★ 1.45
N/A
Revenue
★ $917,734,000.00
$22,503,000.00
Revenue This Year
$2.10
$30.15
Revenue Next Year
$4.63
$384.12
P/E Ratio
$51.83
★ N/A
Revenue Growth
★ 3.29
N/A
52 Week Low
$60.61
$19.13
52 Week High
$103.67
$42.21

Technical Indicators

Market Signals
Indicator
LRN
NAMS
Relative Strength Index (RSI) 37.71 40.84
Support Level N/A $19.36
Resistance Level $86.33 $22.29
Average True Range (ATR) 3.06 1.15
MACD -0.47 0.05
Stochastic Oscillator 11.86 24.37

Price Performance

Historical Comparison
LRN
NAMS

About LRN Stride Inc.

Stride Inc is a technology company providing an educational platform to deliver proprietary and third-party curriculum, software systems, and educational services designed to facilitate individualized learning for students and adults throughout the U.S. The platform delivers products and services to attract, enroll, educate, track progress, and support students. It provides customized solutions to public and private schools, school districts, charter boards, employers, government agencies, and consumers. Its platform addresses two markets in the K-12 space: General Education and Career Learning, with products and services for the General Education market predominantly focused on core subjects for kindergarten through twelfth grade students.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: